Quick Dispatch:
Your surmount-1 tirzepatide non-diabetic obesity weight loss Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-1 tirzepatide non-diabetic obesity weight loss Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ships.
Need Help?
Questions about surmount-1 tirzepatide non-diabetic obesity weight loss Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-1 tirzepatide non-diabetic obesity weight loss Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial in your area.
Weight reduction with different doses of Tirzepatide in Surmount 1
22.06
Tirzepatide vs semaglutide: A new battle in obesity treatment
24.91
Tirzepatide for Obesity Treatment and Diabetes Prevention
27.81
SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants
23.64
Adults with obesity using tirzepatide maintain 'remarkable' weight loss at 88 weeks
20.60
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
25.10
How Did Diabetes Medications Become Weight Loss Meds? Beyond Journal Club on SURMOUNT-1 Trial – Core IM Podcast
21.72
